The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
324 - Dear PAAB, what difference does it make when we combine data from duifferent sections of the TMA (PM). i.e can we put data from the clinical trial section and the adverse event section together since the adverse events are from the clinical trials?
Claims & Support/References for Claims
1
Posts
1
Posters
280
Views
1
Watching
-
In general, clinical trial data and its related adverse events from the same trial may be presented together when taken from the TMA. However, adverse events that are from combined clinical trials may not be presented such that it appears to come from the single source. It should be clearly labeled and appear distinct from the single clinical trial data.
